Author:

Keywords:

Abnormalities, Multiple, Alprostadil, Bartter Syndrome, Double Outlet Right Ventricle, Ductus Arteriosus, Patent, Echocardiography, Humans, Infant, Newborn, Infusions, Intravenous, Male, Natriuresis, Polyuria, Pulmonary Subvalvular Stenosis, Syndrome, Transposition of Great Vessels, Treatment Failure, Vasodilator Agents, Science & Technology, Life Sciences & Biomedicine, Pediatrics, cardiopathy, prostaglandin, Pseudo-Bartter syndrome, side-effects, 1114 Paediatrics and Reproductive Medicine, 1117 Public Health and Health Services, 3213 Paediatrics

Abstract:

We describe a case of iatrogenic pseudo-Bartter syndrome caused by administration of prostaglandin E1 (PGE1 alprostadil). Although the use of i.v. PGE1 is a well-established pharmacological therapy in neonates with a ductus-dependent congenital cardiopathy to ensure ductus-dependent flow, we could only find one other report on pseudo-Bartter syndrome related to PGE1 infusion. CONCLUSION: Primary Bartter syndrome is associated with endogenous increased levels of prostaglandins. Therefore, we postulate that the dose of prostaglandin E1 administered, immaturity and the genetic background are all relevant factors involved in the phenotypic presentation of iatrogenic pseudo-Bartter syndrome in this preterm infant.